 Steven Thorpe
Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 21 | 2026 | 203 | 5.190 |
Why?
| | Soft Tissue Neoplasms | 11 | 2024 | 128 | 3.570 |
Why?
| | Bone Neoplasms | 16 | 2026 | 255 | 2.870 |
Why?
| | Margins of Excision | 3 | 2024 | 51 | 1.730 |
Why?
| | Osteosarcoma | 6 | 2026 | 76 | 1.150 |
Why?
| | Intraoperative Care | 2 | 2024 | 63 | 1.050 |
Why?
| | Frozen Sections | 1 | 2024 | 24 | 0.860 |
Why?
| | Surgical Oncology | 1 | 2024 | 30 | 0.840 |
Why?
| | Sarcoma, Ewing | 3 | 2025 | 103 | 0.520 |
Why?
| | Extremities | 7 | 2023 | 140 | 0.520 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1360 | 0.450 |
Why?
| | Tomography, X-Ray Computed | 3 | 2024 | 2754 | 0.430 |
Why?
| | Killer Cells, Natural | 4 | 2026 | 470 | 0.390 |
Why?
| | Chondrosarcoma | 2 | 2025 | 17 | 0.370 |
Why?
| | Subtalar Joint | 1 | 2012 | 5 | 0.360 |
Why?
| | Flatfoot | 1 | 2012 | 12 | 0.360 |
Why?
| | Sarcoma, Synovial | 2 | 2023 | 20 | 0.350 |
Why?
| | Prognosis | 14 | 2025 | 4312 | 0.340 |
Why?
| | Medical Oncology | 2 | 2025 | 331 | 0.340 |
Why?
| | Subclavian Artery | 1 | 2011 | 28 | 0.330 |
Why?
| | Deltoid Muscle | 1 | 2010 | 6 | 0.330 |
Why?
| | Cellulitis | 1 | 2011 | 53 | 0.330 |
Why?
| | Thoracic Vertebrae | 1 | 2011 | 79 | 0.320 |
Why?
| | Compartment Syndromes | 1 | 2010 | 36 | 0.310 |
Why?
| | Joint Instability | 1 | 2012 | 183 | 0.310 |
Why?
| | Deglutition Disorders | 1 | 2011 | 149 | 0.290 |
Why?
| | Osteomyelitis | 1 | 2011 | 141 | 0.280 |
Why?
| | Humans | 47 | 2026 | 144667 | 0.280 |
Why?
| | Health Status Disparities | 2 | 2021 | 318 | 0.270 |
Why?
| | SEER Program | 4 | 2021 | 226 | 0.270 |
Why?
| | Retrospective Studies | 14 | 2024 | 17149 | 0.250 |
Why?
| | Social Class | 3 | 2023 | 265 | 0.230 |
Why?
| | Neoplasms | 4 | 2022 | 2873 | 0.230 |
Why?
| | Socioeconomic Factors | 4 | 2023 | 1322 | 0.230 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 1145 | 0.220 |
Why?
| | Receptors, Immunologic | 1 | 2026 | 206 | 0.220 |
Why?
| | Knee | 1 | 2025 | 71 | 0.220 |
Why?
| | Follow-Up Studies | 9 | 2024 | 5414 | 0.220 |
Why?
| | Synovitis, Pigmented Villonodular | 1 | 2024 | 3 | 0.210 |
Why?
| | Middle Aged | 18 | 2025 | 35971 | 0.210 |
Why?
| | Giant Cell Tumor of Tendon Sheath | 1 | 2024 | 8 | 0.210 |
Why?
| | Survival Rate | 7 | 2024 | 2089 | 0.200 |
Why?
| | Young Adult | 10 | 2025 | 14122 | 0.200 |
Why?
| | Subcutaneous Fat | 1 | 2024 | 79 | 0.200 |
Why?
| | Cost-Benefit Analysis | 2 | 2024 | 638 | 0.200 |
Why?
| | Thorax | 1 | 2023 | 51 | 0.200 |
Why?
| | Intra-Abdominal Fat | 1 | 2024 | 100 | 0.200 |
Why?
| | Femoral Neoplasms | 1 | 2022 | 10 | 0.190 |
Why?
| | Muscle, Skeletal | 2 | 2025 | 1788 | 0.190 |
Why?
| | Musculoskeletal Diseases | 1 | 2023 | 90 | 0.180 |
Why?
| | Neoplasm Staging | 2 | 2023 | 1465 | 0.180 |
Why?
| | Adult | 16 | 2026 | 40489 | 0.180 |
Why?
| | Bone Diseases | 1 | 2022 | 61 | 0.180 |
Why?
| | Foot Diseases | 1 | 2021 | 17 | 0.170 |
Why?
| | Arthrodesis | 2 | 2012 | 35 | 0.170 |
Why?
| | Male | 22 | 2026 | 72431 | 0.170 |
Why?
| | Knee Joint | 1 | 2025 | 426 | 0.170 |
Why?
| | Osteoarthritis | 1 | 2024 | 196 | 0.170 |
Why?
| | Aged, 80 and over | 6 | 2024 | 8284 | 0.170 |
Why?
| | Neoadjuvant Therapy | 3 | 2021 | 464 | 0.160 |
Why?
| | Female | 22 | 2026 | 78304 | 0.160 |
Why?
| | Radiation Oncology | 1 | 2021 | 83 | 0.160 |
Why?
| | Radiotherapy, Adjuvant | 4 | 2023 | 223 | 0.160 |
Why?
| | Walking | 1 | 2025 | 542 | 0.160 |
Why?
| | Interleukin-15 | 1 | 2020 | 96 | 0.160 |
Why?
| | Body Composition | 1 | 2024 | 689 | 0.160 |
Why?
| | Societies, Medical | 1 | 2024 | 890 | 0.160 |
Why?
| | Hand | 1 | 2021 | 161 | 0.150 |
Why?
| | Reoperation | 2 | 2022 | 624 | 0.150 |
Why?
| | Arteries | 1 | 2021 | 258 | 0.150 |
Why?
| | Insurance, Health | 1 | 2022 | 308 | 0.150 |
Why?
| | Spine | 1 | 2021 | 182 | 0.150 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 152 | 0.150 |
Why?
| | Combined Modality Therapy | 2 | 2025 | 1268 | 0.150 |
Why?
| | Hematologic Neoplasms | 1 | 2021 | 163 | 0.150 |
Why?
| | Thoracic Wall | 1 | 2019 | 21 | 0.150 |
Why?
| | Aged | 11 | 2024 | 25955 | 0.150 |
Why?
| | Thoracic Neoplasms | 1 | 2019 | 39 | 0.140 |
Why?
| | Radiography | 2 | 2012 | 848 | 0.140 |
Why?
| | Health Equity | 1 | 2021 | 132 | 0.140 |
Why?
| | Hemipelvectomy | 1 | 2018 | 1 | 0.140 |
Why?
| | Healthcare Disparities | 2 | 2023 | 736 | 0.140 |
Why?
| | Lower Extremity | 1 | 2022 | 440 | 0.140 |
Why?
| | Vascular Surgical Procedures | 1 | 2021 | 343 | 0.130 |
Why?
| | Free Tissue Flaps | 1 | 2018 | 53 | 0.130 |
Why?
| | Postoperative Complications | 3 | 2019 | 2950 | 0.130 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 915 | 0.130 |
Why?
| | Radiotherapy | 1 | 2018 | 205 | 0.130 |
Why?
| | Adolescent | 10 | 2024 | 22409 | 0.130 |
Why?
| | Osteotomy | 2 | 2022 | 127 | 0.120 |
Why?
| | Child | 10 | 2024 | 22600 | 0.120 |
Why?
| | Transcription Factors | 1 | 2024 | 1726 | 0.120 |
Why?
| | Preoperative Care | 1 | 2019 | 379 | 0.120 |
Why?
| | Lymphocytes | 1 | 2018 | 379 | 0.120 |
Why?
| | C-Reactive Protein | 1 | 2018 | 420 | 0.110 |
Why?
| | Body Mass Index | 1 | 2024 | 2419 | 0.110 |
Why?
| | Databases, Factual | 2 | 2021 | 1494 | 0.110 |
Why?
| | Health Care Costs | 1 | 2019 | 425 | 0.110 |
Why?
| | Incidence | 4 | 2021 | 2892 | 0.110 |
Why?
| | Age Factors | 3 | 2021 | 3329 | 0.100 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 729 | 0.100 |
Why?
| | Infant, Newborn | 5 | 2024 | 6399 | 0.100 |
Why?
| | United States | 8 | 2022 | 16018 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1928 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2022 | 11735 | 0.090 |
Why?
| | Tarsal Bones | 1 | 2012 | 14 | 0.090 |
Why?
| | Neutrophils | 1 | 2018 | 1118 | 0.090 |
Why?
| | Torso | 2 | 2023 | 37 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 6041 | 0.090 |
Why?
| | California | 2 | 2024 | 471 | 0.080 |
Why?
| | Osseointegration | 1 | 2011 | 59 | 0.080 |
Why?
| | Infant | 5 | 2024 | 10023 | 0.080 |
Why?
| | Debridement | 1 | 2011 | 85 | 0.080 |
Why?
| | Immobilization | 1 | 2010 | 53 | 0.080 |
Why?
| | Fatal Outcome | 1 | 2011 | 305 | 0.080 |
Why?
| | Child, Preschool | 5 | 2024 | 11790 | 0.080 |
Why?
| | Necrosis | 1 | 2010 | 243 | 0.080 |
Why?
| | Pain Measurement | 1 | 2012 | 554 | 0.070 |
Why?
| | Cervical Vertebrae | 1 | 2011 | 161 | 0.070 |
Why?
| | Orthopedic Procedures | 1 | 2012 | 242 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2023 | 1322 | 0.070 |
Why?
| | Prospective Studies | 4 | 2024 | 7994 | 0.070 |
Why?
| | Spinal Fusion | 1 | 2011 | 258 | 0.070 |
Why?
| | Recovery of Function | 1 | 2012 | 715 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2026 | 3523 | 0.060 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 643 | 0.060 |
Why?
| | Head and Neck Neoplasms | 1 | 2012 | 562 | 0.060 |
Why?
| | Risk Assessment | 2 | 2018 | 3729 | 0.060 |
Why?
| | Cohort Studies | 3 | 2021 | 5957 | 0.060 |
Why?
| | Sex Factors | 2 | 2021 | 2104 | 0.060 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2025 | 71 | 0.060 |
Why?
| | Pain | 1 | 2011 | 785 | 0.060 |
Why?
| | Disease-Free Survival | 2 | 2020 | 768 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3888 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2922 | 0.050 |
Why?
| | Smoking | 1 | 2011 | 1467 | 0.050 |
Why?
| | Natural Cytotoxicity Triggering Receptor 1 | 1 | 2023 | 3 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 254 | 0.050 |
Why?
| | Mice | 3 | 2026 | 18261 | 0.050 |
Why?
| | Watchful Waiting | 1 | 2024 | 90 | 0.050 |
Why?
| | Electromyography | 1 | 2025 | 416 | 0.050 |
Why?
| | Range of Motion, Articular | 1 | 2025 | 423 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2023 | 195 | 0.050 |
Why?
| | Molecular Targeted Therapy | 1 | 2025 | 437 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1961 | 0.050 |
Why?
| | Antibiotic Prophylaxis | 1 | 2023 | 134 | 0.040 |
Why?
| | Bone Marrow | 1 | 2023 | 306 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2025 | 852 | 0.040 |
Why?
| | Prosthesis Failure | 1 | 2022 | 125 | 0.040 |
Why?
| | Sacrum | 1 | 2022 | 77 | 0.040 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2024 | 426 | 0.040 |
Why?
| | Vascular Grafting | 1 | 2021 | 15 | 0.040 |
Why?
| | Genetic Testing | 1 | 2024 | 480 | 0.040 |
Why?
| | Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2021 | 4 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2024 | 925 | 0.040 |
Why?
| | Animals | 4 | 2026 | 37948 | 0.040 |
Why?
| | Vascular Patency | 1 | 2021 | 121 | 0.040 |
Why?
| | Prosthesis Implantation | 1 | 2022 | 154 | 0.040 |
Why?
| | Insurance Coverage | 1 | 2022 | 243 | 0.040 |
Why?
| | Femur | 1 | 2022 | 251 | 0.040 |
Why?
| | Bone and Bones | 1 | 2023 | 317 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2022 | 355 | 0.040 |
Why?
| | Surgical Wound Infection | 1 | 2023 | 330 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2024 | 586 | 0.040 |
Why?
| | Dogs | 1 | 2020 | 438 | 0.040 |
Why?
| | Sarcopenia | 1 | 2020 | 91 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 1437 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2023 | 472 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 967 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2018 | 315 | 0.030 |
Why?
| | Organ Preservation | 1 | 2018 | 125 | 0.030 |
Why?
| | Perfusion | 1 | 2018 | 249 | 0.030 |
Why?
| | Biocompatible Materials | 1 | 2020 | 436 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 547 | 0.030 |
Why?
| | Tissue Engineering | 1 | 2020 | 441 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1569 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2026 | 4539 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1370 | 0.030 |
Why?
| | Graft Survival | 1 | 2018 | 510 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1079 | 0.030 |
Why?
| | Wound Healing | 1 | 2018 | 352 | 0.030 |
Why?
| | Ischemia | 1 | 2018 | 422 | 0.030 |
Why?
| | Mutation | 1 | 2025 | 4081 | 0.030 |
Why?
| | Medicare | 1 | 2019 | 899 | 0.020 |
Why?
| | Registries | 1 | 2021 | 2392 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2117 | 0.020 |
Why?
| | Signal Transduction | 1 | 2025 | 5185 | 0.020 |
Why?
| | Carboplatin | 1 | 2012 | 161 | 0.020 |
Why?
| | Radiotherapy Dosage | 1 | 2012 | 288 | 0.020 |
Why?
| | Pseudarthrosis | 1 | 2011 | 14 | 0.020 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2012 | 142 | 0.020 |
Why?
| | Spinal Stenosis | 1 | 2011 | 31 | 0.020 |
Why?
| | Radiculopathy | 1 | 2011 | 37 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 256 | 0.020 |
Why?
| | Chemoradiotherapy | 1 | 2012 | 239 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 2446 | 0.020 |
Why?
| | Bone Transplantation | 1 | 2011 | 88 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 3183 | 0.020 |
Why?
| | Risk Factors | 1 | 2022 | 10796 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 7140 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1742 | 0.010 |
Why?
|
|
Thorpe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|